Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

CK1α overexpression correlates with poor survival in colorectal cancer

Authors: Julia Richter, Anna-Laura Kretz, Johannes Lemke, Michael Fauler, Jens-Uwe Werner, Stephan Paschke, Frank Leithäuser, Doris Henne-Bruns, Andreas Hillenbrand, Uwe Knippschild

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Colorectal cancer (CRC) is the fourth leading cause of cancer related deaths worldwide and prognosis in advanced tumor stage still remains poor. Since CK1 isoforms have been reported to be deregulated in several tumor entities CK1 has emerged as a novel drug target in cancer therapy. In this study we set out to investigate whether CK1α might have the potential to serve as prognostic marker.

Methods

CK1α RNA and protein expression levels in healthy and tumor tissue of CRC patients were analyzed using quantitative real-time PCR and Western Blot analysis, respectively. Prognostic relevance was investigated by correlating obtained CK1α expression levels with patients’ survival rate generating Kaplan-Meier survival plots.

Results

It could be shown that CK1α is overexpressed in colorectal tumor tissue compared to normal tissue and CK1α overexpression in tumor tissue correlates with poor survival in CRC patients. Results become more significant when only considering patients with high-grade tumors, as well as patients assigned to UICC II and UICC III stage. Furthermore, Cox regression analysis revealed that CK1α is an independent prognostic factor. In addition, tumors expressing decreased levels of the kinase reveal positive effects on overall survival when localized in the right colon compared to those in the left side.

Conclusion

In summary, this study provides evidence for the first time that CK1α RNA levels might serve as prognostic marker for CRC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
5.
7.
go back to reference Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology. 2003;124(6):1574–94.CrossRefPubMed Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology. 2003;124(6):1574–94.CrossRefPubMed
9.
go back to reference Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer. 2016;15:405–12.CrossRefPubMedPubMedCentral Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer. 2016;15:405–12.CrossRefPubMedPubMedCentral
10.
go back to reference Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev. 2013;39(6):592–601.CrossRefPubMed Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev. 2013;39(6):592–601.CrossRefPubMed
11.
12.
13.
go back to reference Hammond WA, Swaika A, Mody K: Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 2016, 8(1):57–84. Hammond WA, Swaika A, Mody K: Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 2016, 8(1):57–84.
15.
go back to reference Knippschild U, Krueger M, Richter J, Xu P, García-Reyes B, Peifer C, Halekotte J, Bakulev V, Bischof J. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front Oncol. 2014;4(96) Knippschild U, Krueger M, Richter J, Xu P, García-Reyes B, Peifer C, Halekotte J, Bakulev V, Bischof J. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front Oncol. 2014;4(96)
17.
go back to reference Richter J, Rudeck S, Kretz AL, Kramer K, Just S, Henne-Bruns D, Hillenbrand A, Leithauser F, Lemke J, Knippschild U. Decreased CK1delta expression predicts prolonged survival in colorectal cancer patients. Tumour Biol. 2016; Richter J, Rudeck S, Kretz AL, Kramer K, Just S, Henne-Bruns D, Hillenbrand A, Leithauser F, Lemke J, Knippschild U. Decreased CK1delta expression predicts prolonged survival in colorectal cancer patients. Tumour Biol. 2016;
18.
go back to reference Bosmann FT, Carneiro F, Hruban RH, Theise ND: World Health Organization Classification of Tumours, 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2010. Bosmann FT, Carneiro F, Hruban RH, Theise ND: World Health Organization Classification of Tumours, 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2010.
19.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumours: John Wiley & Sons; 2011. Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumours: John Wiley & Sons; 2011.
20.
go back to reference Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, Weinstein JN. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 2009;10:277.CrossRefPubMedPubMedCentral Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, Weinstein JN. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics. 2009;10:277.CrossRefPubMedPubMedCentral
21.
go back to reference Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016; Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;
22.
23.
go back to reference Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55–67.CrossRefPubMed Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55–67.CrossRefPubMed
24.
go back to reference Honaker Y, Piwnica-Worms H. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene. 2010;29(23):3324–34.CrossRefPubMedPubMedCentral Honaker Y, Piwnica-Worms H. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene. 2010;29(23):3324–34.CrossRefPubMedPubMedCentral
25.
go back to reference Jaras M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Pena P, Breyfogle LJ, Hartwell KA, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211(4):605–12.CrossRefPubMedPubMedCentral Jaras M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Pena P, Breyfogle LJ, Hartwell KA, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211(4):605–12.CrossRefPubMedPubMedCentral
26.
go back to reference Lantermann AB, Chen D, McCutcheon K, Hoffmann G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G, Stegemeier F, et al. Inhibition of casein kinase 1 alpha prevents acquired drug resistance to Erlotinib in EGFR-mutant non-small cell lung cancer. Cancer Res. 2015;15:4937–48.CrossRef Lantermann AB, Chen D, McCutcheon K, Hoffmann G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G, Stegemeier F, et al. Inhibition of casein kinase 1 alpha prevents acquired drug resistance to Erlotinib in EGFR-mutant non-small cell lung cancer. Cancer Res. 2015;15:4937–48.CrossRef
27.
go back to reference Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297–315.CrossRefPubMedPubMedCentral Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297–315.CrossRefPubMedPubMedCentral
28.
go back to reference Rena G, Bain J, Elliott M, Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004;5(1):60–5.CrossRefPubMed Rena G, Bain J, Elliott M, Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004;5(1):60–5.CrossRefPubMed
29.
go back to reference Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Gandhi AK, Svinkina T, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;9:183–8.CrossRef Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Gandhi AK, Svinkina T, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;9:183–8.CrossRef
30.
go back to reference Vo MC, Nguyen-Pham TN, Lee HJ, Jaya Lakshmi T, Yang S, Jung SH, Kim HJ, Lee JJ. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget. 2017;8:27252–62.PubMedPubMedCentral Vo MC, Nguyen-Pham TN, Lee HJ, Jaya Lakshmi T, Yang S, Jung SH, Kim HJ, Lee JJ. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget. 2017;8:27252–62.PubMedPubMedCentral
31.
go back to reference Huart AS, MacLaine NJ, Narayan V, Hupp TR. Exploiting the MDM2-CK1alpha protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One. 2012;7(8):e43391.CrossRefPubMedPubMedCentral Huart AS, MacLaine NJ, Narayan V, Hupp TR. Exploiting the MDM2-CK1alpha protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One. 2012;7(8):e43391.CrossRefPubMedPubMedCentral
32.
go back to reference Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–88.CrossRefPubMed Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–88.CrossRefPubMed
33.
go back to reference Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G et al: distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomark Prev 2003, 12(8):755–762. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G et al: distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomark Prev 2003, 12(8):755–762.
34.
go back to reference Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61(5):561–9.PubMed Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61(5):561–9.PubMed
35.
go back to reference Zeng H, Ishaq SL, Zhao FQ, Wright AG. Colonic inflammation accompanies an increase of beta-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice. J Nutr Biochem. 2016;35:30–6.CrossRefPubMed Zeng H, Ishaq SL, Zhao FQ, Wright AG. Colonic inflammation accompanies an increase of beta-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice. J Nutr Biochem. 2016;35:30–6.CrossRefPubMed
36.
go back to reference Yang J, Zhang K, Song H, Wu M, Li J, Yong Z, Jiang S, Kuang X, Zhang T. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget. 2016; Yang J, Zhang K, Song H, Wu M, Li J, Yong Z, Jiang S, Kuang X, Zhang T. Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget. 2016;
37.
go back to reference Gong Y, Dou LJ, Liang J. Link between obesity and cancer: role of triglyceride/free fatty acid cycling. Eur Rev Med Pharmacol Sci. 2014;18(19):2808–20.PubMed Gong Y, Dou LJ, Liang J. Link between obesity and cancer: role of triglyceride/free fatty acid cycling. Eur Rev Med Pharmacol Sci. 2014;18(19):2808–20.PubMed
Metadata
Title
CK1α overexpression correlates with poor survival in colorectal cancer
Authors
Julia Richter
Anna-Laura Kretz
Johannes Lemke
Michael Fauler
Jens-Uwe Werner
Stephan Paschke
Frank Leithäuser
Doris Henne-Bruns
Andreas Hillenbrand
Uwe Knippschild
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4019-0

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine